Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 07-2015 | 07-2014 | 07-2013 | 07-2012 | 07-2011 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 133 | 232 | 396 | 699 | N/A |
| Accounts receivable | -148 | 216 | 156 | 1,389 | -541 |
| Accounts payable and accrued liabilities | -304 | 262 | -277 | -435 | -307 |
| Other Working Capital | -323 | 390 | -223 | 750 | -164 |
| Other Operating Activity | -7,846 | -8,792 | -7,866 | -16,515 | -9,327 |
| Operating Cash Flow | $-8,488 | $-7,692 | $-7,814 | $-14,112 | $-10,339 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -14 | -3 | -6 | -37 | -507 |
| Purchase Sale Intangibles | N/A | N/A | N/A | 0 | 1,336 |
| Other Investing Activity | 0 | 0 | 0 | 0 | 1,336 |
| Investing Cash Flow | $-14 | $-3 | $-6 | $-37 | $829 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 8,243 | 10,153 | N/A | 0 | N/A |
| Other Financing Activity | 67 | 0 | 0 | 43 | 15,431 |
| Financing Cash Flow | $8,310 | $10,153 | $0 | $43 | $15,431 |
| Exchange Rate Effect | -46 | 29 | -9 | -76 | -2 |
| Beginning Cash Position | 6,980 | 4,493 | 4,862 | 19,044 | 13,125 |
| End Cash Position | 6,792 | 6,980 | 4,493 | 4,862 | 19,044 |
| Net Cash Flow | $-142 | $2,458 | $-360 | $-14,106 | $5,921 |
| Free Cash Flow | |||||
| Operating Cash Flow | -8,488 | -7,692 | -7,814 | -14,112 | -10,339 |
| Capital Expenditure | -14 | -3 | -24 | -39 | -507 |
| Free Cash Flow | -8,502 | -7,695 | -7,838 | -14,151 | -10,846 |